Psammaplysene D overcomes sorafenib resistance in liver cancer by targeting FGFR4/CYP26A1-retinoic acid axis to drive ferroptosis
Favorite
Share
More Options
24

Open in WPS to view all 24 pages
This document is user-generated content (UGC). WPS Office is not responsible for its accuracy or copyright. If you believe this content violates your rights, please use the button.
